Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,530.00    0.00 (0.00%)
Bid:
1,529.00
Ask:
1,531.00
Spread: 2.00 (0.131%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Dec 20229:24 amRNSTotal Voting Rights
30th Nov 20227:00 amRNSHikma Injectables Portugal site visit
22nd Nov 202211:38 amRNSHolding(s) in Company
17th Nov 20229:50 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSTrading Statement
13th Oct 20223:00 pmRNSDirectorate Change
5th Oct 202212:16 pmRNSHolding(s) in Company
4th Oct 202210:05 amRNSHolding(s) in Company
3rd Oct 20223:52 pmRNSBlock listing Interim Review
3rd Oct 20223:11 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSDirector changes and update on AGM 2022 resolution
14th Sep 20229:19 amRNSChange of Hikma interim dividend payment date
1st Sep 20222:25 pmRNSTotal Voting Rights
30th Aug 202212:22 pmRNSHikma launches RYALTRIS
23rd Aug 20223:12 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSHalf-year Report
1st Aug 20224:48 pmRNSTotal Voting Rights
18th Jul 20229:26 amRNSNotice of Results
1st Jul 202210:52 amRNSTotal Voting Rights
15th Jun 20223:00 pmRNSCompany Secretary Change
15th Jun 20221:46 pmRNSDirector/PDMR Shareholding
10th Jun 20226:08 pmRNSTransaction in Own Shares
9th Jun 20225:14 pmRNSTransaction in Own Shares
8th Jun 20225:15 pmRNSTransaction in Own Shares
7th Jun 20225:13 pmRNSTransaction in Own Shares
6th Jun 20225:14 pmRNSTransaction in Own Shares
1st Jun 20226:08 pmRNSTransaction in Own Shares
31st May 20225:52 pmRNSTransaction in Own Shares
31st May 202210:00 amRNSDirector/PDMR Shareholding
30th May 20225:23 pmRNSTransaction in Own Shares
27th May 20225:20 pmRNSTransaction in Own Shares
26th May 20225:20 pmRNSTransaction in Own Shares
25th May 20226:03 pmRNSTransaction in Own Shares
24th May 20225:53 pmRNSTransaction in Own Shares
24th May 20227:00 amRNSSiggi Olafsson to step down as Chief Executive
23rd May 20225:51 pmRNSTransaction in Own Shares
20th May 20225:37 pmRNSTransaction in Own Shares
20th May 202212:58 pmRNSResults of EGM
19th May 20226:15 pmRNSTransaction in Own Shares
18th May 20225:22 pmRNSTransaction in Own Shares
17th May 20225:49 pmRNSTransaction in Own Shares
16th May 20226:05 pmRNSTransaction in Own Shares
13th May 20225:41 pmRNSTransaction in Own Shares
12th May 20225:35 pmRNSTransaction in Own Shares
11th May 20225:19 pmRNSTransaction in Own Shares
11th May 20227:00 amRNSShare Buyback Programme
10th May 20225:18 pmRNSTransaction in Own Shares
9th May 20225:59 pmRNSTransaction in Own Shares
6th May 20225:54 pmRNSTransaction in Own Shares
5th May 20225:47 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.